PSA forms complexes with α1-antichymotrypsin in prostate

Prostate

Volumn 73, Issue 2, 2013, Pages 219-226

  Zhu, Lei ^a   Jäämaa, Sari ^a   Af Hällström, Taija M ^a   Laiho, Marikki ^a   Sankila, Anna ^a   Nordling, Stig ^a   Stenman, Ulf Häkan ^a   Koistinen, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ACT; prostate cancer; proximity ligation; serpin; tissue culture

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ARTICLE; CHROMATOGRAPHY; COMPLEX FORMATION; ENZYME ACTIVITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOREACTIVITY; IN SITU PROXIMITY LIGATION ASSAY; MALE; PRIORITY JOURNAL; PROSTATE; PROTEIN SECRETION; TISSUE CULTURE; TISSUE MICROARRAY;

ADULT; AGED; ALPHA 1-ANTICHYMOTRYPSIN; CELL DIFFERENTIATION; HUMANS; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING;

EID: 84871622441     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22560     Document Type: Article

References (47)

1. Lilja H, Ulmert D, Vickers AJ,. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278.
2. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P,. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 2005; 216: 64-81.
3. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O,. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226.
4. Hortin GL, Sviridov D, Anderson NL,. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008; 54: 1608-1616.
5. van Sande M, Van Camp K,. Alpha 1-antitrypsin, alpha 2-macroglobulin and complement C4 in human benign prostatic hyperplasia. Urol Res 1983; 11: 275-277.
6. España F, Sánchez-Cuenca J, Estelles A, Gilabert J, Griffin JH, Heeb MJ,. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. Clin Chem 1996; 42: 545-550.
7. Igawa M, Urakami S, Shiina H, Ishibe T, Shirane T, Usui T, Chodak GW,. Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer. Br J Urol 1996; 77: 107-112.
8. Bjartell A, Björk T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H,. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993; 42: 502-510.
9. Björk T, Bjartell A, Abrahamsson PA, Hulkko S, di Sant'Agnese A, Lilja H,. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427-434.
10. Tanaka M, Suzuki Y, Takaoka K, Murakami S, Suzuki N, Shimazaki J,. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer. Int J Urol 1999; 6: 600-606.
11. Lin VK, Wang SY, Boetticher NC, Vazquez DV, Saboorian H, McConnell JD, Roehrborn CG,. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate 2005; 63: 299-308.
12. Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Sinha P,. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications. Clin Chem 2000; 46: 47-54.
13. Chen Z, Chen H, Stamey TA,. Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin. J Urol 1998; 160: 870-875.
14. Qian Y, Sensibar JA, Zelner DJ, Schaeffer AJ, Finlay JA, Rittenhouse HG, Lee C,. Two-dimensional gel electrophoresis detects prostate-specific antigen-alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Clin Chem 1997; 43: 352-359.
15. Chen Z, Chen H, Stamey TA,. Prostate specific antigen in benign prostatic hyperplasia: Purification and characterization. J Urol 1997; 157: 2166-2170.
16. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM,. " BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41-45.
17. Stenman UH,. Prostate-specific antigen clinical use and staging: An overview. Br J Urol 1997; 79 (Suppl. 1): 53-60.
18. Wu P, Stenman UH, Pakkala M, Närvänen A, Leinonen J,. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 2004; 58: 345-353.
19. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH,. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567-1573.
20. Zhang WM, Leinonen J, Kalkkinen N, Stenman UH,. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997; 33: 87-96.
21. Leinonen J, Zhang WM, Stenman UH,. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099-1103.
22. Zhu L, Koistinen H, Landegren U, Stenman UH,. Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor. Clin Chem 2009; 55: 1665-1671.
23. Leinonen J, Wu P, Stenman UH,. Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries. Clin Chem 2002; 48: 2208-2216.
24. Jäämaa S, Af Hällström TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Zhang Z, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC, Laiho M,. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 2010; 70: 8630-8641.
25. Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, Peltonen K, Andersson LC, Medema RH, Peehl DM, Laiho M,. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 2007; 104: 7211-7216.
26. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH,. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1- antichymotrypsin complex together with free or total PSA. Clin Chem 2003; 49: 97-103.
27. Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT,. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57: 4924-4930.
28. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Jänne OA,. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30: 3962-3976.
29. Dafforn TR, Pike RN, Bottomley SP,. Physical characterization of serpin conformations. Methods 2004; 32: 150-158.
30. Barrett AJ, Starkey PM,. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973; 133: 709-724.
31. Hekim C, Riipi T, Zhu L, Laakkonen P, Stenman UH, Koistinen H,. Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma. Prostate 2010; 70: 482-490.
32. Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H,. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 2008; 68: 945-954.
33. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R,. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166-3170.
34. Boström K, Ockerman PA,. Glycosidases in human semen and male genital organs. Scand J Urol Nephrol 1971; 5: 117-122.
35. du Toit D, Bornman MS, Fourie MH, Aneck-Hahn NH, Pitout MJ,. Sialic acid in semen of normozoospermic men. Arch Androl 1998; 41: 97-101.
36. Paju A, Bjartell A, Zhang WM, Nordling S, Borgström A, Hansson J, Stenman UH,. Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 2000; 157: 2011-2021.
37. Shaw JL, Diamandis EP,. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
38. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH,. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 1998; 44: 2471-2479.
39. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL,. Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483-2491.
40. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT,. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001; 48: 1-6.
41. Abrahamsson PA, Lilja H, Falkmer S, Wadstroöm LB,. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988; 12: 39-46.
42. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A,. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007; 52: 1670-1679.
43. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E,. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.
44. Söderberg O, Gullberg M, Jarvius M, Riddersträle K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U,. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
45. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG,. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial. J Urol 1999; 162: 1346-1351.
46. Okegawa T, Kato M, Nutahara K, Higashihara E,. Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma. Urology 2001; 57: 936-942.
47. Ornstein DK, Englert C, Gillespie JW, Paweletz CP, Linehan WM, Emmert-Buck MR, Petricoin EF III., Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 2000; 6: 353-356.